BI 730460

BI 730460 is an investigational small molecule drug developed by Boehringer Ingelheim. It was primarily studied for the treatment of psoriasis and was classified as an antipsoriatic agent. The exact mechanism of action remains undefined in public sources, but it is described as a small molecule inhibitor. Clinical development included early-phase trials (Phase I) to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers using oral tablet formulations. As of August 2022, clinical development for psoriasis was terminated and no further active development has been reported[1][4][3][5]. There are also references to potential investigation in oncology settings[2], but no advanced clinical data are available.